Navigation Links
Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration

Mechelen, Belgium and Bethesda, Maryland, USA; 29 November 2007 Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, announced today a new collaboration aimed at discovering new treatments for cystic fibrosis. This new agreement between CFFT and Galapagos BioFocus DPI service division is worth up to 5.5 million euros ($8.1 million U.S. dollars) for Galapagos.

The collaboration will combine two key strengths of BioFocus DPI expertise in natural product drug discovery and screening in cells derived from patients. Specifically, the collaboration aims to identify small molecules derived from natural sources that improve the function of a defective protein found in people who have cystic fibrosis. The protein is called CFTR - cystic fibrosis transmembrane conductance regulator. To advance the search for a cure for cystic fibrosis, CFFT funds promising scientific research in the pharmaceutical and biotechnology industry and academia worldwide.

Under the terms of the agreement, Galapagos stands to receive up to 1.6 million ($2.4 million) in upfront and research fees over the next two years, and up to 3.8 million ($5.7 million) in success-based milestone payments, should certain clinical development criteria be met.

This drug discovery collaboration is in addition to an ongoing target discovery program established between CFFT and BioFocus DPI in April 2005.

We are excited to take advantage of the innovative drug discovery approach developed by BioFocus DPI and the companys extensive expertise in natural compounds, said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. By exploring compounds derived from natural sources, our goal is to increase the number and diversity of drug candidates in development to treat cystic fibrosis.

The CFFT drug discovery collaboration is a prime example of the kind of innovation we aimed to achieve through our acquisition strategy, said Onno van de Stolpe, CEO of Galapagos. We have seen a growing interest in natural product based drug discovery since acquiring these capabilities last year. By combining this expertise with our know-how in cell-based screening, we are confident that we will contribute to the advancement of CFFTs drug discovery program in novel ways.


Contact: Lily Mccutchan
Cystic Fibrosis Foundation

Related biology news :

1. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
2. Balzan Foundation announces 2007 winners
3. Keck Foundation funds study of biological interactions with nanomaterials
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. PETA awards $120,000 to Duluth Foundation for advancing non-animal tests
6. Simons Foundation awards Emory scientists $3M for autism gene research
7. Arizona State University launches biofuel initiative with BP and Science Foundation Arizona
8. Life-saving clean water project secures $13M from Bill & Melinda Gates Foundation
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. LaserCard Corporation Announces Expansion of Middle East Project
11. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
Post Your Comments:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today ... Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an ... turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of turfgrass ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
Breaking Biology Technology: